A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
Latest Information Update: 06 Aug 2026
At a glance
- Drugs Ozureprubart (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
Most Recent Events
- 03 Aug 2026 Planned number of patients changed from 180 to 240.
- 03 Aug 2026 Planned End Date changed from 28 Apr 2028 to 9 Jun 2028.
- 03 Aug 2026 Planned primary completion date changed from 30 Jun 2027 to 7 Jun 2027.